Epiomic Epidemiology Series: Growth hormone deficiency Forecast in 19 Major Markets 2018–2028

August 2018 | 80 pages | ID: EFEED0295BAEN
Black Swan Analysis limited

Abstracts

Black Swan Analysis Epiomic Epidemiology Series Forecast Report on Growth Hormone Deficiency in 19 Major Markets

Growth Hormone Deficiency (GHD) results from the destruction of normal pituitary and hypothalamic tissue and is characterized by the inadequate secretion of growth hormone (GH) from the anterior pituitary gland. GHD can occur at any point during an individual’s life but is primarily defined as being of childhood onset (CO) or adult onset (AO). Age at onset tends to denote a different underlying pathology for the deficiency. The majority of CO is congenital, whereas AO forms tend to be acquired or idiopathic. For congenital forms, there are three types linked with different genetic inheritance patterns. Acquired types tend to arise from a variety of tumours of the hypothalamus/pituitary as well as brain trauma, surgery/treatment of extra-cranial tumours, etc.

This report provides the current prevalent population for GHD across 19 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, GHD patients grouped by various features and comorbidities have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for GHD include:

• Diabetes mellitus and other issues with glucose regulation (including IGT and metabolic syndrome)
• Hypertension
• Obesity
• Osteopaenia, osteoporosis and increased frequency of fractures
• Liver disease
• Cerebrovascular diseases
• Cardiovascular diseases

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Ability to quantify patient populations in global GHD market to target the development of future products, pricing strategies and launch plans.
• Further insight into the prevalence of the subdivided types of GHD and identification of patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Better understanding on the impact of specific co-morbid conditions on the prevalent population of GHD patients.
• Identification of GHD patient sub-populations that require treatment.
• Better understanding of the specific markets that have the largest number of GHD patients.

Contents

INTRODUCTION

CAUSE OF THE DISEASE

RISK FACTORS & PREVENTION

DIAGNOSIS OF THE DISEASE

VARIATION BY GEOGRAPHY/ETHNICITY

DISEASE PROGNOSIS & CLINICAL COURSE

KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE

METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS

TOP-LINE PREVALENCE FOR GROWTH HORMONE DEFICIENCY

FEATURES OF GROWTH HORMONE DEFICIENCY PATIENTS

AETIOLOGY

OTHER FEATURES

COMORBIDITIES OF GROWTH HORMONE DEFICIENCY PATIENTS

HORMONAL DISTURBANCES

BONE STRUCTURE ABNORMALITIES

OTHER COMORBIDITIES

ABBREVIATIONS USED IN THE REPORT

OTHER BLACK SWAN SERVICES & SOLUTIONS

REPORTS & PUBLICATIONS

ONLINE EPIDEMIOLOGY DATABASES

ONLINE PHARMACEUTICAL PRICING DATABASE

REFERENCES

APPENDIX

List Of Tables

LIST OF TABLES AND FIGURES

Table 1. Prevalence of GHD, total (000s)
Table 2. Prevalence of GHD, males (000s)
Table 3. Prevalence of GHD, females (000s)
Table 4. GHD patients by aetiology, total (000s)
Table 5. Acquired GHD patients by aetiology, total (000s)
Table 6. GHD patients with pituitary/hypothalamus tumours by pituitary adenoma functional status, total (000s)
Table 7. GHD patients with pituitary/hypothalamus tumours by pituitary adenoma size, total (000s)
Table 8. GHD patients by onset type, total (000s)
Table 9. GHD patients by BMI, total (000s)
Table 10. GHD patients by pituitary hormonal deficiencies, total (000s)
Table 11. GHD patients with TSH deficiency, total (000s)
Table 12. GHD patients with ACTH deficiency, total (000s)
Table 13. GHD patients with LH/FSH deficiency, total (000s)
Table 14. GHD patients with ADH deficiency, total (000s)
Table 15. GHD patients by bone density status, total (000s)
Table 16. GHD patients with bone fractures, total (000s)
Table 17. GHD patients with bone fractures by site, total (000s)
Table 18. GHD patients with diabetes mellitus, total (000s)
Table 19. GHD patients with dyslipidaemia, total (000s)
Table 20. GHD patients with hypertension, total (000s)
Table 21. GHD patients with metabolic syndrome, total (000s)
Table 22. GHD patients with visual field loss, total (000s)
Table 23. GHD patients with cerebrovascular disease, total (000s)
Table 24. GHD patients with arthritis, total (000s)
Table 25. Abbreviations and acronyms used in the report
Table 26. USA prevalence of GHD by 5-yr age cohort, males (000s)
Table 27. USA prevalence of GHD by 5-yr age cohort, females (000s)
Table 28. Canada prevalence of GHD by 5-yr age cohort, males (000s)
Table 29. Canada prevalence of GHD by 5-yr age cohort, females (000s)
Table 30. France prevalence of GHD by 5-yr age cohort, males (000s)
Table 31. France prevalence of GHD by 5-yr age cohort, females (000s)
Table 32. Germany prevalence of GHD by 5-yr age cohort, males (000s)
Table 33. Germany prevalence of GHD by 5-yr age cohort, females (000s)
Table 34. Italy prevalence of GHD by 5-yr age cohort, males (000s)
Table 35. Italy prevalence of GHD by 5-yr age cohort, females (000s)
Table 36. Spain prevalence of GHD by 5-yr age cohort, males (000s)
Table 37. Spain prevalence of GHD by 5-yr age cohort, females (000s)
Table 38. UK prevalence of GHD by 5-yr age cohort, males (000s)
Table 39. UK prevalence of GHD by 5-yr age cohort, females (000s)
Table 40. Poland prevalence of GHD by 5-yr age cohort, males (000s)
Table 41. Poland prevalence of GHD by 5-yr age cohort, females (000s)
Table 42. Netherlands prevalence of GHD by 5-yr age cohort, males (000s)
Table 43. Netherlands prevalence of GHD by 5-yr age cohort, females (000s)
Table 44. Russia prevalence of GHD by 5-yr age cohort, males (000s)
Table 45. Russia prevalence of GHD by 5-yr age cohort, females (000s)
Table 46. Turkey prevalence of GHD by 5-yr age cohort, males (000s)
Table 47. Turkey prevalence of GHD by 5-yr age cohort, females (000s)
Table 48. Japan prevalence of GHD by 5-yr age cohort, males (000s)
Table 49. Japan prevalence of GHD by 5-yr age cohort, females (000s)
Table 50. China prevalence of GHD by 5-yr age cohort, males (000s)
Table 51. China prevalence of GHD by 5-yr age cohort, females (000s)
Table 52. South Korea prevalence of GHD by 5-yr age cohort, males (000s)
Table 53. South Korea prevalence of GHD by 5-yr age cohort, females (000s)
Table 54. India prevalence of GHD by 5-yr age cohort, males (000s)
Table 55. India prevalence of GHD by 5-yr age cohort, females (000s)
Table 56. Australia prevalence of GHD by 5-yr age cohort, males (000s)
Table 57. Australia prevalence of GHD by 5-yr age cohort, females (000s)
Table 58. Brazil prevalence of GHD by 5-yr age cohort, males (000s)
Table 59. Brazil prevalence of GHD by 5-yr age cohort, females (000s)
Table 60. Mexico prevalence of GHD by 5-yr age cohort, males (000s)
Table 61. Mexico prevalence of GHD by 5-yr age cohort, females (000s)
Table 62. Argentina prevalence of GHD by 5-yr age cohort, males (000s)
Table 63. Argentina prevalence of GHD by 5-yr age cohort, females (000s)